Compass Therapeutics' tovecimig shows promise in biliary cancer, boasting a 17.1% response rate. Despite high risks, I ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, ...

Eraglusib with gemcitabine and nab-paclitaxel achieved statistical significance in the first-line treatment of metastatic ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...